2017
116. Sheffler DJ, Nedelcovych MT, Williams R, Turner SC, Duerk BB, Robbins MR, Jadhav SB, Niswender CM, Jones CK, Conn PJ, Nathan Daniels R, Lindsley CW. Corrigendum to “Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0] -based series and other piperidine bioisosteres.” Bioorg Med Chem Lett. 2017 May 1;27(9):2079 [PubMed]
115. Dash RP, Rais R. “P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine-Significance of zeitgeber time on pharmacokinetics.” Pharmacol Res, 2017, Jul: 121:251-252 [PubMed]
114. Zou MF, Cao J, Abramyan A, Kopajtic T, Zanettini C, Guthrie D, Rais R, Slusher BS, Shi L, Loland C, Newman A. “Structure-activity relationship studies on a series of 3α-[bis(4-fluorophenyl)methoxy]tropanes and 3α-[bis(4-fluorophenyl)methylamino]tropanes as novel atypical dopamine transporter (DAT) inhibitors for the treatment of cocaine use disorders.” J Med Chem. 2017, Dec 28;60(24): 10172-10187. [PubMed]
113. Nedelcovych M, Dash RP, Tenora L, Zimmermann SC, Gadiano AJ, Garrett C, Alt J, Hollinger KR, Pommier E, Jancarik A, Rojas C, Thomas AG, Wu Y, Wozniak K, Majer P, Slusher BS, Rais R. “Enhanced Brain Delivery of (2-(phosphonomethyl)pentanedioic acid) following Intranasal Administration of its y-substituted Ester Prodrugs.” Mol Pharm. 2017, Oct 2:14(10):3248-3257 [PubMed]
112. Rais R, Vavra J, Tichy T, Dash RP, Gadiano AJ, Tenora L, Monincova L, Barinka C, Alt J, Zimmermann SC, Slusher CE, Wu Y, Wozniak K, Majer P, Tsukamoto T, Slusher BS. “Discovery of a para-acetoxy-benzyl ester prodrug of a hydroxamate-based Glutamate Carboxypeptidase II inhibitor as oral therapy for neuropathic pain.” J Med Chem, 2017, Sept 28;60(18):7799-7809 [PubMed]
111. Nedelcovych MT, Tenora L, Kim BH, Kelschenbach J, Chao W, Hadas E, Jancarik A, Prchalova E, Zimmermann SC, Dash RP, Gadiano AJ, Garrett C, Furtmuller G, Oh B, Brandacher G, Alt J, Majer P, Volsky DJ, Rais R, Slusher BS. “N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-L-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.” J Med Chem. 2017, Aug 24;60(16):7186-7198 [PubMed]
110. Nedelcovych M, Manning AA, Semenova S, Gamaldo C, Haughey NJ, Slusher BS. “The Psychiatric Impact of HIV.” ACS Chemical Neuroscience, 2017, Jul 19;8(7):1432-1434 [PubMed]
109. Baxter VK, Glowinski R, Braxton AM, Potter MC, Slusher BS, Griffin DE. “Glutamine antagonist-mediated immune suppression decreases pathology but delays virus clearance in mice during nonfatal alphavirus encephalomyelitis.” Virology, 2017, 508, 134-149 [PubMed]
108. B [PubMed]
107. Gamo NJ, Birknow MR, Sullivan D, Kondo MA, Horiuchi Y, Sakurai T, Slusher BS, Sawa A. “Valley of death: A proposal to build a “translational bridge” for the next generation.” Neuroscience Research, 2017, 115, 1-4 [PubMed]
106. Kremer JC, Prudner BC, Lange SE, Bean GR, Schultze MB, Brashears CB, Radyk MD, Redlich N, Tzeng SC, Kami K, Shelton L, Li A, Morgan Z, Bomalaski JS, Tsukamoto T, McConathy J, Michel LS, Held JM, Van Tine BA. “Arginine deprivation inhibits the Warburg effect and upregulates glutamine anaplerosis and serine biosynthesis in ASS1-deficient cancers.” Cell Rep. 2017, Jan 24; 18(4):991-1004 [PubMed]
105. Figuera-Losada M, Thomas AG, Stathis M, Stockwell BR, Rojas C, Slusher BS. “Development of a primary microglia screening assay and its use to characterize inhibition of system xc- by erastin and its analogs.” Biochemistry and Biophysics Reports, 2017, Jan 17;9:266-272 [PubMed]
104. Yokley BH, Hartman M, Slusher BS. “Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.” ACS Chemical Neuroscience, 2017, Mar 15;8(3):429-431 [PubMed]
103. Date AA, Rais R, Babu T, Ortiz J, Kanvinde P, Thomas AG, Zimmermann SC, Gadiano AJ, Halpert G, Slusher BS, Ensign LM. “Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.” J Control Release, 2017, Jan 31, [PubMed]